| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1040171874 |
| P356 | DOI | 10.1007/S11060-014-1685-X |
| P698 | PubMed publication ID | 25519302 |
| P2093 | author name string | Jeffrey S Weber | |
| Geoffrey T Gibney | |||
| Peter A Forsyth | |||
| Sarah Sloot | |||
| Arnold B Etame | |||
| Kamran A Ahmed | |||
| Nikhil G Rao | |||
| Prakash Chinnaiyan | |||
| Siriporn Sarangkasiri | |||
| Jessica M Freilich | |||
| Nicholas Figura | |||
| P2860 | cites work | Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib | Q24594790 |
| Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma | Q24597152 | ||
| Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 | ||
| Distinct sets of genetic alterations in melanoma | Q29614965 | ||
| On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases. | Q30838330 | ||
| Determinants of survival in patients with brain metastases from cutaneous melanoma | Q33794890 | ||
| Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. | Q34634256 | ||
| Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study | Q34658082 | ||
| Melanoma brain metastases and vemurafenib: need for further investigation | Q36512866 | ||
| Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy. | Q36934327 | ||
| Vemurafenib and radiosensitization. | Q43840156 | ||
| Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial | Q44442912 | ||
| Vemurafenib and radiation therapy in melanoma brain metastases | Q44534087 | ||
| Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib. Two case reports | Q45150448 | ||
| Gamma knife radiosurgery for malignant melanoma brain metastases. | Q46341945 | ||
| Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study | Q46463625 | ||
| Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma | Q47632181 | ||
| Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival | Q48355816 | ||
| Vemurafenib for Melanoma Metastases to the Brain | Q48763254 | ||
| Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. | Q52964781 | ||
| Cutaneous Toxic Effects Associated With Vemurafenib and Inhibition of the BRAF Pathway | Q53178811 | ||
| Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05 | Q73764877 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 121-126 | |
| P577 | publication date | 2014-12-18 | |
| P1433 | published in | Journal of Neuro-Oncology | Q15752119 |
| P1476 | title | LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases | |
| P478 | volume | 122 |
| Q28079359 | Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG) |
| Q39750563 | BRAF Mutation Is Associated with Improved Local Control of Melanoma Brain Metastases Treated with Gamma Knife Radiosurgery. |
| Q37090142 | BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis |
| Q28076667 | BRAF inhibitors and radiotherapy for melanoma brain metastases: potential advantages and disadvantages of combination therapy |
| Q48011082 | Brain metastasis from melanoma: the prognostic value of varying sites of extracranial disease |
| Q38548397 | Clinical Management of Multiple Melanoma Brain Metastases: A Systematic Review. |
| Q48508820 | Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy. |
| Q47768004 | Combined irradiation and targeted therapy or immune checkpoint blockade in brain metastases: toxicities and efficacy |
| Q38905543 | Controversies in the Therapy of Brain Metastases: Shifting Paradigms in an Era of Effective Systemic Therapy and Longer-Term Survivorship |
| Q35916658 | Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases. |
| Q47653459 | Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies. |
| Q54950354 | Mechanisms and Therapy for Cancer Metastasis to the Brain. |
| Q31098294 | Melanoma brain metastases : Treatment options |
| Q49966288 | Multiple primary malignancies and prolonged survival in a patient with widespread metastatic cutaneous melanoma |
| Q38918333 | Radiosurgery/stereotactic radiotherapy in combination with immunotherapy and targeted agents for melanoma brain metastases |
| Q38652041 | Radiotherapy with BRAF inhibitor therapy for melanoma: progress and possibilities |
| Q48354660 | Stereotactic Radiosurgery for Melanoma Brain Metastases: A Comprehensive Clinical Case Series |
| Q49956245 | Targeted therapy of brain metastases: latest evidence and clinical implications |
| Q90474060 | The impact of current treatment modalities on the outcomes of patients with melanoma brain metastases: A systematic review |
| Q38975455 | Use of Systemic Therapy Concurrent With Cranial Radiotherapy for Cerebral Metastases of Solid Tumors. |
Search more.